Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, significantly increasing the risk of stroke, systemic embolism, and cardiovascular complications. Yet many patients remain untreated or undertreated due to concerns around bleeding with current oral anticoagulants.
J&J’s approach to atrial fibrillation
Johnson & Johnson, in collaboration with Bristol Myers Squibb, is leading the Librexia AF trial to evaluate the safety and efficacy of an investigational oral FXIa inhibitor, for stroke prevention in patients with AF. The study was designed to reflect a real-world AF patient population, including a representative group of patients.
Targeting Factor XIa represents a potential new therapeutic pathway that may reduce the risk of thrombotic events while preserving the body’s natural ability to stop bleeding.
Targeting Factor XIa may reduce the risk of thrombotic events while preserving the body’s natural ability to stop bleeding.
